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INTRODUCTION   
 
Deep vein thrombosis (DVT) refers to the formation of one or more blood clots 
(a blood clot is also known as a “thrombus,” while multiple clots are called 
“thrombi”) in one of the body’s large veins, most commonly in the lower limbs 
(e.g., lower leg or calf).  
The clot(s) can cause partial or complete blocking of circulation in the vein, 
which in some patients leads to pain, swelling, tenderness, discoloration, or 
redness of the affected area, and skin that is warm to the touch. However, 
approximately half of all DVT episodes produce few, if any, symptoms. For 
some patients, DVT is an “acute” episode (that is, the symptoms go away once 
the disease is successfully treated), but roughly 30 percent of patients suffer 
additional symptoms, including leg pain and swelling, recurrent skin 
breakdown, and painful ulcers. In addition, individuals experiencing their first 
DVT remain at increased risk of subsequent episodes throughout the remainder 
of their lives. 
The most serious complication that can arise from DVT is a pulmonary 
embolism (PE) which occurs in over one-third of DVT patients. A PE occurs 
when a portion of the blood clot breaks loose and travels in the bloodstream, 
first to the heart and then to the lungs, where it can partially or completely block 
a pulmonary artery or one of its branches. A PE is a serious, life-threatening 
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complication with signs and symptoms that include: shortness of breath, rapid 
heartbeat, sweating, and/or sharp chest pain (especially during deep breathing). 
Pulmonary embolism frequently causes sudden death, particularly when one or 
more of the vessels that supply the lungs are completely blocked by the clot. 
Those who survive generally do not have any lasting effects because the body’s 
natural mechanisms tend to resorb (or “lyse”) blood clots. However, in some 
instances, the blood clot in the lung fails to completely dissolve, leading to a 
chronic serious complication that can cause chronic shortness of breath and 
heart failure. DVT and PE are commonly grouped together and sometimes 
referred to as “venous thromboembolism” (VTE)16 
AIMS AND OBJECTIVES 
1. To study the Natural history of Acute and Chronic DVT. 
2. To study the various treatment modalities in Acute DVT. 
3. To study the outcome following treatment in Acute DVT. 
REVIEW OF LITERATURE    
HISTORY   
Deep vein thrombosis (DVT) is a common disease. The first well-documented 
case of DVT was reported during the middle Ages: in 1271, Raoul developed a 
unilateral oedema in the ankle, which then extended to the leg. The number of 
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reported DVT cases steadily increased thereafter, particularly in pregnant and 
postpartum women. 
 During the first half of the 20th century, well before the discovery of 
anticoagulants, many therapeutic approaches were used, and arose from the 
pathologic hypotheses that prevailed at their time.  
Despite the development of anticoagulants, and the fact that they were thought 
to dramatically decrease DVT mortality, numerous complementary treatments 
have also been developed during the last 50 years: they include vena cava clips 
and surgical thrombectomy, and are intended to decrease mortality or to prevent 
late complications. Most of these treatments have now been abandoned, or even 
forgotten. The first description of a case truly compatible with a DVT first 
appears during the Middle age. In the manuscript of Guillaume de Saint Pathus 
entitled ‘La vie et les miracles de Saint Louis’, it is reported that, in 1271, 
Raoul, a 20-year-old Norman cobbler suffered unilateral pain and swelling of 
the right calf that subsequently extended up to the thigh Thus, this first reported 
case of effective treatment of DVT might not be the most reproducible. Thus, 
although venous thrombosis is a frequent disease, it appears that cases clearly 
compatible with the diagnosis of DVT were reported before the description of 
the case of Raoul17. After this first unquestionable description by Guillaume de 
Saint Pathus, the number of reported cases of DVT increased rapidly and the 
first pathologic hypotheses arose, leading to the first treatment attempts. During 
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the Renaissance, physicians hypothesized that pregnancy-related DVT, which 
was the leading, or even only, cause of reported DVT at that time, was the 
consequence of retention of ‘evil humors’. It was also thought that postpartum 
DVT was caused by retention of unconsumed milk in the legs (‘milk leg’). 
Thus, in the late 1700s, breast-feeding was encouraged to prevent DVT. Of 
course, the most frequent and popular method among physicians to discharge 
evil humors during the 17th century was bloodletting .This technique was used 
to treat DVT and many other diseases until the end of the 19th century. In 1676, 
Wiseman suggested that DVT was the consequence of an alteration of blood, 
and then, in 1793, Hunter hypothesized that it was an occlusion of the vein by 
blood clots. In 1784, well before Virchow demonstrated the relationship 
between DVT and fatal PE (1856), Hunter had performed venous ligations 
above thrombosis, to prevent extension of clots. In the absence of any other 
truly effective treatment for preventing fatal PE, this technique became more 
widely used at the end of the 19th century. It was assumed to be of ‘immense 
value in reducing the incidence of PE. The ligation could be performed at the 
femoral, common femoral, iliac and inferior vena cava (IVC) levels in cases of 
proximal thrombosis, and more rarely in cases of distal thrombosis, although 
this latter therapeutic intervention remained controversial. This surgical 
treatment was still widely used until the mid-20th century in association with, or 
instead of, anticoagulants. For fear of thrombus migration, strict bed rest was 
prescribed, and constituted, at least from the end of the 19th century, the 
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cornerstone of DVT treatment. Thus, in cases of DVT, the patient's lower limbs 
were set in iron splints to prevent any movement. Special, reclining, orthopaedic 
beds were also used to favour venous return .However, during the 19th century, 
the most commonly accepted underlying mechanism for DVT was the 
inflammation of the vein wall provoked by and/or provoking an infectious 
phenomenon. This was consistent with the observation that DVT is, in many 
cases, associated with fever, and frequently occurred postpartum, after – septic 
– surgical procedures, or during bed rest for an infectious disease. 
Consequently, the treatments prescribed involved anti-inflammatory medication 
and the prevention and treatment of infection. Overall, prior to the 1930s, before 
the introduction of anticoagulants, the most common treatment for DVT mainly 
relied on:  
(i) Bed rest to fix the thrombus in place;  
(ii) Elevation of the extremity involved to favour venous return. 
(iii) Application of heat with warm compresses to reduce vasospasm 
and to increase collateral circulation.  
 
Because major risk factors for DVT had already been identified, 
most currently used thromboprophylactic measures were already 
known and applied in hospitalized cases.  
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By the middle of the 19th century, the major pathologic mechanisms of venous 
thrombosis had been discovered. They were first summarized in the famous 
Virchow's triad (1856), theorized by Andral in 1831 and which Virchow 
probably never described.  
However, it was only towards the 1920s that a consensus appeared regarding 
the three factors contributing to thrombosis: stasis, vessel wall alteration, and 
hypercoagulability. During this period, a number of therapeutic breakthroughs, 
most of them discovered by accident, revolutionized DVT treatment 
ANATOMY OF VEINS OF LOWER LIMB  
The lower limb consists of two main types of veins4  
a) Superficial vein 
b) Deep vein 
c) Perforators 
SUPERFICIAL VEIN:- 
They include great and small saphenous veins and their tributaries. They are 
located within the subcutaneous tissue of superficial facia, on the surface of 
deep fascia. They are thick walled because of the presence of smooth muscle 
and some fibrous and elastic tissues in their walls. Valves are numerous in the 
distal parts of these veins than their proximal parts. A Large Proportion of their 
blood is drained into deep veins through perforating veins. 
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DEEP VEIN:- 
The deep veins accompany the major arteries and their branches and are usually 
paired. They contain valves to prevent reflux of blood distally. 
Deep veins are, 
 Medial & Lateral plantar  
 Dorsalis pedis 
 Anterior &Posterior Tibial 
 Peroneal  
 Popliteal and femoral veins and their tributaries. 
They are surrounded by powerful surrounding muscles. The valves are 
numerous in the deep veins than in the superficial veins. They are more efficient 
channels than superficial veins because of the driving force of muscular 
contraction. 
PERFORATORS:- 
The superficial and deep veins are connected by perforator veins. They have 
valves which permit only unidirectional flow of blood from superficial to deep 
veins. They are mentioned below. 
Indirect Perforating veins:- 
These veins connect the superficial with the deep veins through the muscular 
veins. 
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Direct Perforating veins:- 
These will connect the superficial veins directly to deep veins.There are about 
five perforators along the great saphenous vein and one along the small 
saphenous vein. 
The small direct perforating veins are follows 
1. In the Thigh:- The Adductor canal Perforator connects the great saphenous 
vein with the femoral vein in the lower part of the adductor canal. 
2. Below the Knee:-One Perforator connects the great saphenous vein or the 
posterior arch veins with the posterior tibial vein. 
3. In the Leg:-A lateral perforator is present at the junction of the middle and 
lower thirds of the leg.it connects the small saphenous vein or one of its 
tributaries with peroneal vein. 
Medially there are three perforators which connect the posterior arch vein with 
the posterior tibial vein. 
a) The upper medical perforator lies at the junction of the middle and lower 
thirds of the leg. 
b) The Middle medical perforator lies above the medical malleolous. 
c) The Lower medial perforator lies in the posteroinferior to the medial 
malleolus. 
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Factors helping the Venous return:- 
General factors: _ 
1. Negative intrathoracic Pressure, which is made more negative during 
inspiration 
2. Arterial pressure and overflow from capillary bed. 
3. Compression of veins accompanying arteries by arterial pulsation. 
4. The presence of valves which support and divide the long column of blood in 
to shorter columns. These also maintain a unidirectional flow. 
Local factors:- 
These are Venous, Muscular, and Fascial 
Venous:-The veins of the lower limb are more muscular than the veins of any 
other part of the body. They have greater number of valves. Superficial veins 
are connected to deep veins by perforators. 
Muscular:- When the limb is active muscular contraction compress the deep 
veins and drives the blood in them upwards. 
Fascial:-The tight sleeve of deep fascia makes muscular compression of the 
veins much more effective by limiting outward bulging of the muscles. 
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EPIDEMIOLOGY 
INCIDENCE: 
Incidence of lower extremity DVT is highly dependent on the population 
studied, their underlying risk factors and the means by which DVT is 
documented. True estimates of the incidence of DVT are limited by the few 
population based studies, the clinically silent nature of most thrombosis and the 
need for objective documentation of the diagnosis. Even the interpretation of 
methodologically sound studies is complicated by inconsistent inclusion of 
DVT and or pulmonary embolism, differing exclusion or inclusion of recurring 
DVT and variable age ranges, community based studies of hospitalised patients 
have suggested firs episode of DVT to have a crude annual incidence of 56/1 
Lakh.2 
AGE:  
Age has been most consistently associated with an increased risk of DVT. The 
incidence of DVT increases exponentially with age. This increased risk appears 
related to several age- associated factors, including decreased mobility, an 
increased number of major thrombotic risk factors, age- related 
hypercoagulability, and changes in the venous system.2 
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GENDER: 
Gender differences in the incidence of DVT have been variable and may be 
related to other risk factors. Although Coon and associates found higher 
frequency if DVT in young women, one half of Thromboembolic events in 
women less than 40 years old were associated with pregnancy. Some have noted 
no significant differences in incidence between men and women. However, 
incidence rates in young populations are higher in women during the child 
bearing years and may be higher in men over 45-60 years of age1,5,7 
AETIOPATHOGENESIS 
Aetiology:- 
The three factors described by Virchow over a century ago are still relevant in 
the development of venous thrombosis. They are 
a) Changes in the vessel wall (endothelial damage) 
b) Stasis, which is diminished blood flow through the veins3 
c) Coagulability of blood (thrombophilia) 
These are together known as Virchow triad. 
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The most important factor is hospital admission for the treatment of a medical 
or surgical condition. Injury, especially fractures of the lower limb and pelvis, 
pregnancy and the oral contraceptive pill are well recognised predisposing 
factors. 
Endothelial damage is now known to be critically important, the interaction of 
the endothelium with the inflammatory cells or previous deep vein damage, 
renders the endothelial surface hypercoagulable and less fibrinolytic. Biological 
injury to endothelium may have very important role in the origin DVT. Venus 
endothelium is normally antithrombotic, producing PGI 2, Thrombomodulin, 
TPA and Glycosaminoglycan CO factors of antithrombin. Under conditions 
favouring thrombosis the endothelium becomes prothrombotic producing tissue 
factor Von Willebrand Factor and fibronectin. Leukocytes may be a key 
mediator of both endothelial injury and hypercoagulability, with the early 
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phases of thrombosis marked by increases in permeability followed by 
leukocyte adhesion migration and endothelial disruption. 
Stasis is a predisposing factor seen in many conditions, especially in the 
postoperative period, in patients with heart failure and in those with atrial 
ischemia. Stasis alone is inadequate stimulus in the absence of low levels of 
activated coagulation factors. Although stasis may facilitate endothelial 
leukocyte adhesion and cause endothelial hypoxia leading to a pro coagulant 
state, its most important role may be in permitting the accumulation of 
Activated coagulation factors in areas prone to thrombosis. 
A number of conditions are associated with hypercoagulability 
(Thrombophilia).deficiencies of antithrombin. Activated protein C &S have all 
shown to predispose to venous thrombosis in young patients. A thrombophilic 
cause should be sought in any patient presenting with an episode of venous 
thrombosis who gives a family history of DVT or in whom there is no other 
predisposing factor. 
All though the development of DVT is probably multifactorial, immobility (and 
hence stasis) remains one of the most important factors. DVT is recognised as a 
complication of long-haul flights and other forms of travel. 
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RISK FACTORS 
PATIENT FACTORS:- 
a) Age 
b) Obesity 
c) Varicose veins 
d) Immobility 
e) Pregnancy 
f) Puerperium 
g) High dose oestrogen therapy 
h) Previous DVT or Pulmonary embolism 
i) High dose oestrogen therapy 
j) Thrombophilia (Deficiency of Anti thrombin III, Protein C or S, factor V 
Leiden mutation) 
DISEASE OR SURGICAL PROCEDURE: 
a) Trauma or surgery, especially of pelvis, hip and lower limb. 
b) Malignancy, especially pelvis, hip and lower limb. 
c) Heart failure 
d) Recent MI 
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e) Paralysis of lower limb 
f) Inflammatory bowel disease 
g) Nephrotic syndrome 
h) Polycythaemia 
i) Paraproteinaemia 
j) Paroxysmal nocturnal haemoglobinuria 
k) Homocystinaemia 
PATHOLOGY:- 
A thrombus often develop in the soleal veins of the calf, initially as a 
platelet aggregate. Subsequently, fibrin and red cells form a mesh until 
the lumen of the vein wall occludes. The coralline thrombus then 
progress as a propagated loose red fibrin clot containing many red 
cells. This is likely to extend up to the next large venous branch and it 
is possible for the clot to break off and embolise to the lung as a 
pulmonary embolism. In this situation the embolus arising from the 
lower leg veins become detached, passes through the large veins of the 
limb and vena cava, through the right heart and lodges in the 
pulmonary arteries. This may totally occlude perfusion to all or part of 
one or both lungs (pulmonary embolism).Acute Right heart 
obstruction may lead to sudden collapse and death. Lung infarction is 
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rare as the lung has a dual blood supply(Bronchial and Pulmonary 
arteries).Moderate sized emboli can cause Pyramidal-shaped infarcts. 
CLINICAL PRESENTATION AND NATURAL HISTORY OF 
ACUTE DVT:- 
Introduction:- 
The spectrum of venous thromboembolism (VTE) includes both deep 
venous thrombosis (DVT) and pulmonary embolism (PE).Many 
episodes are asymptomatic and the symptoms of acute DVT includes 
oedema, pain and erythema are non –specific. At least three quarters 
of patients having lower extremity symptoms consistent with DVT 
have non thrombotic cause of their symptoms. Confirmatory test is 
therefore always required both to ensure appropriate treatment of 
those with confirmed DVT and to prevent the complications of 
inappropriate anticoagulation in those with other disorders. The 
treatment of DVT is aimed at preventing its complications-PE, 
recurrent DVT, Post-thrombotic syndrome and Death. 
Clinical Presentation of Acute DVT:- 
Clinical presentation of acute DVT varies with the anatomic 
distribution extend and degree of occlusion of thrombus. Symptoms 
may accordingly range from their absence to massive swelling and 
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cyanosis with impending venous gangrene (phlegmasia cerulea 
dolens)6,8. 
 
Signs and symptoms include pain oedema erythema tenderness, fever 
prominence superficial veins pain with passive dorsiflexion of foot 
(Homans sign) and peripheral cyanosis. Phlegmasia cerulea dolens is 
characterised by the triad of massive swelling cyanosis and pain, it is 
the most severe form of DVT and results from near complete 
thrombosis of an extremities and venous outflow. Advanced cases it is 
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marked by severe venous hypertension with collateral and micro 
vascular thrombosis leading to venous gangrene. 
 
 
Three patterns of thrombosis are commonly recognised they are 
1) Isolated calf vein thrombosis 
2) Femoro popliteal 
3) Illeo femoral 
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Calf veins are the most common site of origin, although 40% of the 
proximal thrombi arise primarily in the femoral or iliac veins 
presumably in the regions behind the valves. 
Investigations:- 
 D dimer 
 Doppler 
 Duplex 
 MRI Venography 
 Impedance Plethysmography 
 Contrast Venography 
D –dimer 9 
Elevated D- dimer is not necessarily a risk factor causing VTE , but it 
should be used and interpreted as a marker of hypercoagulability. D-
dimer is formed when fibrin is proteolysed by plasmin. The presence 
of elevated levels of D-dimer in the circulation signifies that 
endogenous fibrinolysis of a venous thrombus has yielded cross-
linked fibrin. The degree of D-dimer elevation with VTE may depend 
on the extent of disease , the duration of symptoms , and the use of 
anticoagulants , with lower D-dimer levels associated with less 
extensive disease , longer duration of symptoms, and anticoagulant 
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use. Using D-dimer to preselect patients likely to have DVT has 
gained considerable interest in an effort to reduce costs and expedite 
patient work-up. The D-dimer assays currently available are 
turbidimetry, ELISA, latex particle agglutination, fluorescence 
immunoassay and immunofiltration tests. Each assay has a 
corresponding normal reference range which is typically not 
interchangeable. There are situations where D-dimer assay may be 
falsely positive. These situations include pregnancy, malignancy, 
recent postoperative state and total bilirubin greater than 2mg/dl. 
Further confounding factors may include the age of the clot as 
significant declines in the D-dimer level may occur with time, position 
of the clot and heparin use. Despite its limitations, D-dimer is a useful 
tool to rule out DVT as long as the threshold is set low enough to keep 
the sensitivity high. 
 
DUPLEX18,27- Duplex ultrasound combines compression using real-
time B-mode ultrasound with Doppler venous outflow detection .Its 
lack of radiation, portability, non-invasiveness and cost-effectiveness 
has made it superior to contrast venography. It also has the ability to 
distinguish non-vascular pathology such as inguinal adenopathy, 
Baker’s cyst, abscesses and hematomas. The sensitivity of 
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compression sonography is high for proximal DVT and lower for non-
occluding or isolated calf vein thrombosis. The pitfalls of venous 
duplex imaging include misidentification of veins ,duplicated vein 
systems, systemic illness or hypovolemia decreasing venous 
distension , suboptimal imaging in obese or oedematous patients , or 
areas not amenable to compression such as the iliac veins and 
adductor canal. 
Normal venous flow assessment:- 
Spontaneity – Spontaneous flow without augmentation 
Phasicity – flow changes with respiration 
Compression – Transverse plane 
Augmentation – compression distal to site of examination, patency 
below site of examination 
Valsalva –deep breath, strain, while holding the breath patency of 
abdominal and pelvic veins 
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MAGNETIC RESONANCE VENOGRAPHY20 
MRV has gained momentum in recent years for the detection of DVT. 
In addition to been less invasive than contrast venography MRV 
overcomes some of the limitation of Duplex and Impedance 
Plethysmography. Since MRV directly visualises the thrombus even 
non flow limiting thrombi should be detectable unlike with impedance 
Plethysmography. MRV should also be able to detect thrombus 
proximal to the inguinal ligament, an area which has been problematic 
for duplex in the past. MRV results are also independent of the 
technologists experience and availability. Its limitation includes high 
cost, patients with implants and renal insufficiency since gadolinium 
is associated with nephrogenic systemic fibrosis. 
 
CONTRAST VENOGRAPHY:- 
Contrast venography has by default been long hailed as the gold 
standard for detection of symptomatic DVT.As of late, its current role 
in diagnosis of DVT has been largely relegated to one of historical 
interest25. The study is limited in its practicality by both the 
availability of highly sensitive non-invasive studies and by its own 
disadvantages, including the risk of phlebitis, IV contrast load with 
associated risk of nephrotoxicity and allergic reaction, Increased cost 
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and the need for adequate IV access. Of the available methods of 
performing venography 2 techniques have been emerged as dominant. 
First technique described by rabenow-paulin, involves spot films 
whereas the second technique involves long-leg films. Rarely is CV a 
first line study, a role for CV is still exist when non-invasive studies 
are unavailable , non-diagnostic or in the presence of a clinical 
condition known to produce false results(e.g. –D dimer levels post 
operatively or during pregnancy, compression of the iliac veins in 
pregnant or recently postpartum women on  a MRV study etc. 
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IMPEDENCE PLETHYSMOGRAPHY (IPG):22- 
IPG is based upon the physiological principle that the impedance 
between 2 points on the skin of an extremity will decrease as the 
volume of blood contained in the extremity increases. The technique 
examines great at which venous outflow occurs, thereby deducing the 
presence or absence of venous outflow obstruction. The presence of 
DVT in the major vessels of the lower extremity including the 
popliteal vein and proximally, should reduce the rate of venous 
outflow and subsequently affect the tracing. In the instance of non-
flow limiting thrombi, the study will be negative. Its limitation include 
inability to detect DVT distal to popliteal vein. 
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COMPLICATION;- 
1) Pulmonary embolism11: - The potentially life threatening 
consequences of PE make it the most important short term 
complication of acute DVT. Symptomatic PE accompanies 
approximately in 10% of DVTs and hospital discharge data 
suggests 23 per 1 lakh population. Most common signs of PE are 
Tachypnoea and tachycardia. Less common signs include syncope, 
Hypoxemia and sudden hypotension. The use of a validated pretest 
probability score is recommended for as the first step in the work 
up of patients suspected to have PE. 
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CT SHOWING PULMONARY EMBOLISM 
 
RADIOLOGICAL SIGNS IN PULMONARY EMBOLISM  
 Fleischner sign – enlarged pulmonary artery 
 Hampton hump- peripheral wedge air space opacity and 
implies lung infarction 
 Westermark sign – regional oligaemia  
 Palla sign- enlarged right descending pulmonary artery 
 Chang sign- dilated right pulmonary artery with sudden cut 
off 
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WELLS CLINICAL DECISION RULE:- 
Clinical signs and symptoms of 
DVT, minimal swelling of the leg 
and pain on palpitation of the deep 
leg veins  
3.0 
Pulmonary embolism more likely 
than an alternative diagnosis 
3.0 
Heart beat frequency >100 beats 
per minute 
1.5 
Recent immobilization or surgery 
within < 4 weeks 
1.5 
Documented history of DVT and 
or PE 
1.5 
Haemoptysis 1.0 
Recent history of malignancy <6 
months (treatment or palliative 
treatment) 
1.0 
Clinical score for Pulmonary embolism:- 
Low   <_ 2 
Moderate 2.0-6.0 
High >_6 
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POST THROMBOTIC SYNDROME  
 
Affects 43% patients with DVT within 2 years. 
Higher incidence in those with proximal (iliofemoral) DVT. 
Characterised by painful oedematous legs, paraesthesia, cramps, pruiritis, 
hyperpigmentation, varicosities, Ulceration and recurrent infection.20 
Inflammation is thought to play a role as well as damage to venous valves from 
the thrombus itself. Valvular incompetence combined with persistent venous 
obstruction from thrombus increases the pressure in veins and capillaries. 
Venous hypertension induces rupture of small superficial veins, subcutaneous 
haemorrhage, and an increase in vascular permeability.  
RISK FACTORS-Age >65 , proximal DVT , second DVT in same leg as first 
DVT , persistent DVT symptoms within one month of DVT diagnosis, obesity , 
poor quality of anticoagulation control during the first 3 months of treatment. 
 
PREVENTION – early treatment of acute and recurrent DVTTREATMENT – 
ambulation, compression stockings, anticoagulants, and catheter directed 
thrombolysis. 
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RECURRENT VENOUS THROMBOSIS 
Recurrent Thrombotic events compete with recanalization early after an acute 
DVT. Most clinicical studies have included both symptomatic recurrent DVT 
and PE, with rates depending on treatment, proximal or distal location of 
Thrombus and duration of follow up.  
Fortunately standard anticoagulation is very effective in preventing recurrent 
VTE while patients are being treated. The risk of recurrence is highly related to 
the underlying Thrombotic risk factors.  
Recurrent VTE in the setting of Thrombosis isolated to the calf veins requires 
special consideration. Limited data suggest that isolated calf vein Thrombosis is 
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associated with less extensive activation of coagulation than proximal venous 
Thrombosis, perhaps implying some difference in Pathophysiology10.  
At least two types of calf vein Thrombosis may be differentiated – those with 
involvement of the paired posterior tibial and peroneal venae commitantes and 
those isolated to the veins draining the gastrocnemial and soleal muscles and 
their natural history may be different.  
Recognised Thrombophilic states, particularly the factor 5 Leiden mutation, 
lupus anticoagulant and Homocystinaemia have been associated with recurrent 
Thrombo embolic events. 
Recanalization and recurrent Thrombosis are related and failure of 
recanalization is now recognised as an independent predictor of recurrent DVT. 
The presence of ongoing hypercoagulability is in fact, perhaps a better predictor 
of the risk of recurrent VTE. 
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VARICOSE VEIN
 
 
Varicose vein occurs as a complication of Deep vein Thrombosis due to 
 destruction of valves by thrombus.  
TREATMENT:- 
A) MEDICAL :- 
 HEPARIN 
 LMWH 
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 ORAL ANTICOAGULANTS 
B) ENDOVASCULAR INTERVENTION 
C) SURGICAL THROMBECTOMY 
The objectives of treatment in patients with VTE are  
a) To prevent death from pulmonary embolism 
b) To prevent recurrent VTE 
c) To prevent post-phlebitic syndrome 
The mainstay of medical therapy has been anticoagulation since the introduction 
of heparin in the 1930s.Other anticoagulation drugs have subsequently been 
added to the treatment armamentarium over the years, such as vitamin K 
antagonists and low-molecular-weight heparin (LMWH). 
Anticoagulant therapy is recommended for 3-12 months depending on site of 
thrombosis and on the ongoing presence of risk factors. If DVT recurs, if a 
chronic hypercoagulability is identified, or if PE is life threatening, lifetime 
anticoagulation therapy may be recommended. This treatment protocol has a 
cumulative risk of bleeding complications of less than 12%. 
CONTRAINDICATION OF ANTICOAGULATION:- 
Absolute contraindications include  
Intracranial bleeding 
Severe active bleeding 
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Recent brain, eye, or spinal cord surgery 
Pregnancy 
Malignant hypertension.  
Relative contraindications include  
Recent major surgery 
Recent cerebrovascular accident 
Severe thrombocytopenia 
HEPARIN THERAPY:- 
Heparin is a heterogeneous mixture of polysaccharide fragments with varying 
molecular weights but with similar biological activity21.  
The larger fragments exert their anticoagulant effect by interacting with 
antithrombin III (ATIII) to inhibit thrombin. ATIII, the body’s primary 
anticoagulant, inactivates thrombin and inhibits the activity of activated factor 
X in the coagulation process.23,24 
Heparin prevents extension of the thrombus and has been shown to significantly 
reduce (but not eliminate) the incidence of fatal and nonfatal pulmonary 
embolism and recurrent thrombosis. 
Heparin Protocol:- 
Administer initial intravenous heparin bolus 5000U 
*Administer continuous intravenous heparin infusion: commence at 42 ml/h of 
20000U (1680U/h) in 500 ml of two-thirds dextrose and one-third saline (a 24 
hour heparin dose of 40320U), except in following patients in whom heparin 
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infusion is commenced at a rate of 31 mL/h (1240U/h, a 24 hour dose of 
29760U) 
*Patient who have undergone surgery within the previous 2 weeks  
*Patients with a previous history of peptic ulcer disease or gastrointestinal and 
genitourinary bleeding. 
*Patient with recent stroke (thrombotic stroke within 2 weeks previously) 
*Patients with a platelet count <150 x 10*9/L 
*Patients with miscellaneous reasons for a high risk of bleeding (e.g.:-hepatic 
failure, renal failure, or Vitamin K deficiency) 
*Adjust heparin dose by use of aPTT. The aPTT test is performed in all patients 
as follows, 
*4-6 hours after commencing heparin, the heparin dose is then adjusted 
*4-6 hours after the first dose adjustment, then as indicated by the nomogram 
for the first 24 hours of therapy. 
Thereafter once daily, unless the patient is sub therapeutic (< 1.5 times the mean 
normal control value for the thromboplastin reagent being used) in which case 
the aPTT test is repeated 4-6 hours after the heparin dose is increased. 
Although there is a strong correlation between sub therapeutic aPTT values and 
recurrent Thromboembolism, the relationship between sub therapeutic aPTT 
and bleeding is less definite. Indeed bleeding during heparin therapy is more 
closely related to underlying clinical risk factors than to aPTT elevation above 
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the therapeutic range. Studies confirm that weight and age > 65 are independent 
risk factors for bleeding on heparin. 
Complications of Heparin therapy:- 
 Bleeding 
 Thrombocytopenia 
 Osteoporosis  
 Heparin induced thrombocytopenia 
Low Molecular weight Heparin:- 
Low-molecular-weight heparins (LMWHs) are a new class of anticoagulants 
derived from unfractionated heparin (UFH). They have a number of advantages 
over UFH that have led to their increasing use for a number of thromboembolic 
indications13. 
They differ from UFH in many ways, of particular importance are the 
following:- 
*Increased bioavailability 
*Prolonged half life 
*Predictable clearance enabling once or twice daily injection, and *predictable 
antithrombotic effect based on body weight permitting   treatment without 
laboratory monitoring. 
*Ability to inactivate platelet bound factor Xa, resistance to inhibition by 
platelet factor IV, and their decreased effect on platelet function and vascular 
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permeability, possibly accounting for less haemorrhagic effects at comparable 
antithrombotic doses. 
Though there are complications like bleeding, Heparin induced 
thrombocytopenia, osteoporosis, with LMWH the incidence is much lower 
when compared to UFH. 
If heparin induce thrombocytopenia occurs LMWH should be stopped and an 
alternative such as argatraban or hirudin derivative should be commenced. 
ORAL VITAMIN K ANTAGONIST:- 
There are 2 distinct chemical groups of oral anticoagulants 
4-hydroxy coumarin derivatives (e.g.; warfarin) 
Indanedione derivatives (e.g.; Phenindione) 
The coumarin derivatives are the anticoagulants of choice because they are 
associated with fewer non haemorrhagic adverse effects than the Indanedione 
derivatives10. 
Anticoagulation effect of warfarin id mediated by the inhibition of Vitamin K 
dependant coagulation factors, II,IV,IX, and X. 
The anticoagulant effect of warfarin is delayed until the normal clotting factors 
are cleared from circulation, and the peak effect does not occur until 36-72 
hours after drug administration. Heparin and warfarin treatment should overlap 
by 4-5 days. 
The lab test most commonly used to measure the effects of warfarin is the one 
stage PT test. To promote standardization of the PT monitoring, WHO (World 
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Health organization) enveloped an international reference thromboplastin from 
human brain tissue and recommended at the PT ratio to be expressed as the 
International normalized ratio, or INR. The monitoring and dosing of the oral 
anticoagulant therapy is done according to the INR value. 
Warfarin is administered in an initial small doses for the first 2 days, then the 
dose adjusted according to the INR value. Heparin therapy is discontinued in 
the 4th or 5th day following initiation of warfarin therapy, provided the INR is 
in the therapeutic range (INR 2-3) 
The dose response relationship of warfarin therapy varies widely between 
individuals and therefor the dose must be carefully monitored to prevent under 
dosing or over dosing. Patient should be warned against taking any new drugs 
without the knowledge of their attending physician in view of drug interaction. 
Once the anticoagulant effect and patients warfarin dose requirements are 
stable, the INR should be monitored at regular intervals throughout the course 
of warfarin therapy for VTE for maintenance of the narrow therapeutic range. 
COMPLICATIONS OF WARFARIN 
 Major adverse effects are bleeding 
 Coumarin induced skin necrosis – it is a serious complication, most 
commonly seen in women. It occurs between  3 to 10 days after therapy 
has commenced. Most common locations  are areas with abundant 
subcutaneous tissue such as the abdomen, buttocks, thighs and the breast. 
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The antidote used for vitamin K antagonists is Vitamin K1. 
FACTOR XA AND DIRECT THROMBIN INHIBITORS:- 
Fondaparinux 
Fondaparinux, a direct selective inhibitor of factor Xa, overcomes many of the 
aforementioned disadvantages of low-molecular-weight heparins(LMWHs). 
Pharmacokinetic studies of fondaparinux reveal that only a single-daily 
subcutaneous dose is required. Furthermore, a single dose of 7.5mg is effective 
over a wide range of patient weights between 50 and 100 kg. Daily doses of 5 
mg or 10 mg are appropriate for patients who weigh less or more than that 
weight range.  
Heparin-induced thrombocytopenia (HIT) has not been reported. Therapeutic 
monitoring of laboratory parameters such as the prothrombin time or activated 
partial thromboplastin time (aPTT) is also not required. 
 In some regions, the cost of therapy 
With fondaparinux is less than enoxaparin when it is being used to bridge 
therapy to a vitamin K antagonist (VKA). 
The combination of two factor Xa inhibitors may be an effective treatment 
strategy for acute venous thromboembolism (VTE). 
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Rivaroxaban 
Rivaroxaban (Xarelto) is an oral factor Xa inhibitor approved by the FDA in 
November 2012 for treatment of DVT or pulmonary embolism (PE) and for 
reduction of the risk of recurrent DVT and PE after initial treatment. 
Approval for this indication was based on studies totalling 9478 patients with 
DVT or PE. Participants were randomly assigned to receive Rivaroxaban, a 
combination of enoxaparin and a VKA (eg, warfarin), or a placebo. Study 
endpoints were designed to measure the number of patients who experienced 
recurrent symptoms of DVT, PE, or death after receiving treatment. Data from a 
pooled analysis of the EINSTEIN-DVT [7] and EINSTEIN-PE [8] trials 
suggested that Rivaroxaban is as effective in preventing VTE recurrence as 
enoxaparin followed by a VKA and may be associated with less bleeding in 
addition, the data suggested that there are no grounds 
for avoiding Rivaroxaban use in high-risk groups 26(eg, fragile patients, cancer 
patients, and patients with a large clot). 
Approximately 2.1% of patients treated with rivaroxaban experienced recurrent 
DVT or PE, compared with 1.8-3% treated with the enoxaparin and VKA 
combination. 
Additionally, results from extended treatment demonstrated a reduced risk of 
recurrent DVT and PE. Approximately 1.3% in the rivaroxaban group 
experienced recurrent DVT or PE, compared with 7.1% in the placebo group. 
 
50 
 
Apixaban 
In March 2014, the FDA approved apixaban (Eliquis) for the additional 
indication of prophylaxis of DVT and PE in adults who have undergone hip- or 
knee-replacement surgery.  
Support for this new indication was a result of the ADVANCE 1, 2, and 3 
clinical trials that enrolled nearly 12,000 patients. 
Apixaban was originally approved by the FDA in December 2012 for the 
prevention of stroke and systemic embolism in patients with 
nonvalvular atrial fibrillation. 
In August 2014, apixaban was approved for treatment of DVT and PE. The 
approval for treatment of PE and prevention of recurrence was based on the 
outcome of the AMPLIFY (Apixaban for the Initial Management of Pulmonary 
Embolism and Deep-Vein Thrombosis as First-Line Therapy) and AMPLIFY-
EXT (extended treatment) studies, in which apixaban therapy was compared 
with enoxaparin and warfarin treatment.  
The AMPLIFY study showed that, in comparison with the standard 
anticoagulant regimen, apixaban therapy resulted in a 16% reduction in the risk 
of a composite endpoint that included recurrent symptomatic venous 
thromboembolism (VTE) or VTE-associated death.  
Data from the AMPLIFY-EXT trial showed that extended anticoagulation (12 
months) with apixaban shortened hospital stays, reduced symptomatic recurrent 
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venous thromboembolism or all-cause death without an associated increase in 
major episodes of haemorrhage when compared with placebo. 
Dabigatran 
Dabigatran (Pradaxa) inhibits free and clot-bound thrombin and thrombin-
induced platelet aggregation. This agent was FDA approved in 2010 to reduce 
the risk of stroke and systemic embolism in patients with nonvalvular atrial 
fibrillation. In April 2014, it was approved for the treatment of DVT and PE in 
patients who have been treated with a parenteral anticoagulant for 5-10 days.  
Additionally, it was approved to reduce the risk of DVT and 
PE recurrence in patients who have been previously treated. Approval was 
based on results from 4 global phase III trials that showed Dabigatran was non 
inferior to warfarin and had a lower risk of major or clinically relevant bleeding 
compared with warfarin. There have been reports of severe and fatal bleeding in 
users of the drug. 
The RE-COVER and RE-COVER II trials included patients with DVT and PE 
who were treated with parenteral anticoagulant therapy for 5-10 days. Results 
showed Dabigatran was non inferior to warfarin in reducing DVT and PE after a 
median of 174 days of treatment with a lower risk of bleeding compared with 
warfarin. 
The RE-SONATE trial and RE-MEDY trials included patients (n=2856) with 
acute DVT and PE who had completed at least 3 months of anticoagulant 
therapy. Results from this trial showed Dabigatran was non inferior to warfarin 
52 
 
in the extended treatment of VTE and carried a lower risk of major or clinically 
relevant bleeding than warfarin.  
Edoxaban 
Edoxaban (Savaysa) was approved by the FDA in January 2015 for the 
treatment of DVT and PE in patients who have been initially treated with a 
parenteral anticoagulant for 5-10 days. Approval was based on the Hokusai-
VTE study that included 4,921 patients with DVT and 3,319 patients with PE. 
Among patients with PE, 938 had right ventricular dysfunction, as assessed by 
measurement of N-terminal pro-brain natriuretic peptide (NT-proBNP) levels. 
There was a 3.3% rate of recurrent VTE in this subgroup in those who received 
Edoxaban compared to 6.2% in the group that received warfarin. The 
investigators concluded that Edoxaban was not only non inferior to high-quality 
standard warfarin therapy but also caused significantly less bleeding in a broad 
spectrum of patients with VTE, including those with severe PE. 
Reversal of Anticoagulation 
Anticoagulation-related major bleeding is associated with an increased risk of 
death and thrombotic events, independent of the class of anticoagulant used. 
Although older agents of anticoagulation and their reversal are well studied, the 
newer agents lack similar antidotes. With the increasing use of non–vitamin K 
antagonist oral anticoagulants (NOAC), the number of patients who require 
reversal of their anticoagulant effects can be expected to rise. 
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 The following section describes the reversal agents for both older and new 
anticoagulants. 
Heparin 
Heparin has a relatively short half-life of about 60–90 minutes and, therefore, 
the anticoagulant effect of therapeutic doses of heparin will mostly be 
eliminated at 3-4 hours after termination of continuous intravenous 
administration. For a more immediate neutralization of heparin, protamine 
sulfate can be administered at a dose of 1 mg for every 100 units of heparin.  
Lower molecular weight heparins 
Currently, there are no specific antidotes to low molecular weight heparins. 
Recombinant FVIIa (rVIIA) has been shown to stop bleeding in patients 
anticoagulated with fondaparinux; however, no randomized controlled trials on 
such patients have been conducted. 
Warfarin 
Vitamin K 
In patients with clinically significant bleeding, vitamin K can be used to reverse 
the anticoagulant effect of vitamin K antagonists (VKA). Vitamin K can be 
given orally or intravenously. The parenteral route has a more rapid onset; 
however, it is associated with a slightly increased risk of allergic reaction. 
Fresh frozen plasma (FFP) 
In case of a life-threatening emergency, FFP can be used for the reversal of 
VKA. FFP contains all the coagulation factors in normal concentrations. 
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However, FFP should be used with caution, as it has the potential to cause 
volume overload, allergic reaction, and transfusion-related reactions. 
Prothrombin complex concentrates (PCCs) 
In the case of serious and life-threatening bleeding, immediate correction of the 
international normalized ratio (INR) can be achieved by the administration of 
PCCs. These contain 3 or 4 of the vitamin K–dependent coagulation factors, as 
well as proteins C and S. In a prospective study, administration of PCCs has 
been shown to result in sustained haemostasis in patients using VKA. 
Non–vitamin K antagonist oral anticoagulants (NOACs) 
The new oral anticoagulant factor Xa or IIa inhibitors have numerous 
advantages over traditional VKAs, including rapid therapeutic effectiveness, 
ease of dosing, and lack of monitoring. Until recently, there were no approved 
drug-specific reversal agents for the NOACs.  
A number of drugs are currently under development. [145, 146] 
Due to the short half-life of FXa inhibitors, discontinuation of the drugs suffice 
in clinical situations in which there is time to await spontaneous clearance. 
Currently, PCCs can be used to address severe bleeding in patients taking 
NOACs when administered in high enough dosages. Some guidelines suggest 
an initial dose of 25 to 50 U/kg of PCCs in life-threatening emergencies, to be 
repeated if necessary. 
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Idarucizumab (Pradbind) 
Idarucizumab is a humanized antibody fragment directed against Dabigatran. 
This agent has been shown to completely reverse the anticoagulant effect of 
Dabigatran within minutes; on October 16, 2015, it was approved by the FDA 
as an antidote for Dabigatran. [147, 148, 149, 150] 
Andexanet alfa 
Andexanet alfa is a recombinant, modified FXa molecule that acts as a decoy 
protein that is catalytically inactive but has a high affinity for FXainhibitors. It 
is being developed as an antidote for apixaban, Edoxaban, and Rivaroxaban. 
Andexanet alfa has been shown to reverse the anticoagulant effects of apixaban 
and Rivaroxaban in human volunteers, and more studies are ongoing. 
Aripazine(PER977, ciraparantag) 
Aripazine is a synthetic small molecule that has broad activity against both old 
(Heparin, low molecular weight heparin) and new oral anticoagulants 
(Dabigatran, Rivaroxaban, apixaban, Edoxaban). A 2014 study of human 
volunteers demonstrated that administration of Aripazine reversed the 
prolonged clotting time caused by Edoxaban. 
ENDOVASCULAR INTERVENTION:- 
Percutaneous transcatheter treatment of patients with deep venous thrombosis 
(DVT) consists of thrombus removal with catheter-directed thrombolysis30, 
mechanical thrombectomy, angioplasty, and/or stenting of venous obstructions. 
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In some cases, patients may also be given pulmonary embolism (PE) 
prophylaxis by means of filter placement in the inferior venacava27. 
Indications for Percutaneous Transcatheter Treatment include the relatively 
rare  
Phlegmasia or symptomatic inferior vena cava thrombosis that responds poorly 
to anticoagulation alone, symptomatic iliofemoral or femoropopliteal DVT in 
patients with a low risk of bleeding. In the last groups, the goal is to reduce the 
high risk of PTS or to achieve symptomatic relief in conjunction with 
angioplasty or stent placement. 
Phlegmasia cerulea dolens treatment 
Phlegmasia cerulea dolens is an indication for emergency catheter-directed 
thrombolysis in patients with moderate or low bleeding risks. This 
recommendation is based on reports of limb salvage, which stand in contrast to 
the high rates of limb amputation and death seen with standard therapies. 
Surgical thrombectomy remains an effective option in patients at high risk for 
haemorrhagic complications, although it often results in incomplete thrombus 
removal, recurrent DVT, and an increased incidence of systemic complications. 
Inferior vena cava thrombosis treatment 
Acute or subacute inferior vena cava thrombosis that causes at least moderate 
pelvic congestion, limb symptoms, or compromised visceral venous drainage 
warrants catheter-directed thrombolysis. Involvement of the suprarenal cava, 
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renal veins, and/or hepatic veins may precipitate acute renal or hepatic failure. 
Thrombus that involves the upper inferior vena cava may make it impossible to 
place an inferior vena cava filter for PE prophylaxis. 
Subacute and chronic Iliofemoral DVT treatment 
Subacute and chronic iliofemoral DVT is accompanied by moderate to severe 
pelvic or limb symptoms with a low bleeding risk. Because recanalization of the 
iliac vein is unlikely, iliofemoral DVT often produces valvular reflux. This 
combination of outflow obstruction and reflux is associated with the most 
symptomatic forms of PTS. In this situation, patients have venous damage, and 
the alternative is venous bypass. In these instances, catheter-directed 
thrombolysis is seldom expected to completely clear the vein, but it is often 
used to remove any acute component of thrombus and to uncover chronic 
stenoses or underlying anatomic abnormality as an adjunct to angioplasty or 
stent placement. Compared with systemic thrombolysis, catheter-directed 
thrombolysis improves the preservation of valve competence (44% vs 13%). 
Acute iliofemoral or femoropopliteal DVT treatment 
Whether catheter-directed thrombolysis is indicated in the relatively common 
event of acute iliofemoral or femoropopliteal DVT is somewhat controversial. 
Catheter-directed thrombolysis may be superior to anticoagulation with regard 
to decreasing the incidence of recurrent DVT and PTS. However, the evidence 
is not conclusive. 
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Catheter-directed thrombolysis improves thrombus clearance compared with 
systemic thrombolysis.  
Asymptomatic DVT 
Asymptomatic DVT is not considered an indication for endovascular 
intervention at this time. The incidence of PTS at 5 years after asymptomatic 
calf or proximal DVT is low, at 5%.  The absence of symptoms may reflect the 
lack of the obstructive effect that is proposed to initiate the syndrome. On the 
other hand, while the incidence of PTS may not warrant endovascular treatment, 
some reports suggest that treatment of asymptomatic DVT may be necessary to 
prevent most cases of PE that are diagnosed at autopsy. Asymptomatic proximal 
DVT had a mortality risk of 13.7% versus 2% in patients without DVT  
Contraindications for percutaneous transcatheter treatment they are the same as 
those for thrombolysis in general.  
Absolute contraindications include:- 
Active internal bleeding or disseminated intravascular coagulation, 
A cerebrovascular event, trauma, and neurosurgery within 3 months. 
Relative contraindications 
They include major surgery within 10 days, obstetric delivery, major trauma, 
organ biopsy, intracranial or spinal cord tumour, uncontrolled hypertension, 
major GI haemorrhage (within 3 months), serious allergic reaction to a 
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thrombolytic agent, known right-to-left cardiac or pulmonary shunt or left-heart 
thrombus, and an infected venous thrombus.  
Unfortunately, most patients with DVT have absolute contraindications to 
thrombolytic therapy. Thrombolytic therapy is also not effective once the 
thrombus is adherent and begins to organize. Venous thrombi in the legs are 
often large and associated with complete venous occlusion. In these cases, 
thrombolytic agents act on the surface of the clot but may not be able to 
penetrate and lyse the entire thrombus. 
Technique:- 
Access to the iliofemoral venous circulation is usually obtained via the popliteal 
vein, using ultrasonographic guidance, although the common femoral, tibial, or 
internal jugular veins are also used. When thrombolysis is planned, use of 
ultrasonography and a micropuncture 21-gauge needle are recommended to 
minimize bleeding risk.  
Diagnostic venography is used to identify the extent of DVT. Fluoroscopic 
guidance is the most accurate and straightforward means of placing infusion 
catheters or devices. A sheath is placed, and a multiple–side-hole catheter or 
wire is used to maximize delivery of the thrombolytic agent to the surface area 
of the thrombus. 
During thrombolysis, patients remain on bed rest, with frequent monitoring of 
vital signs and puncture sites performed. Pericatheter oozing, enlarging 
hematoma, or evidence of gastrointestinal or genitourinary bleeding warrant 
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immediate attention. Additional punctures, particularly arterial or intramuscular 
ones, should be avoided. 
A separate IV access facilitates blood sampling, which is performed at 6-hour 
intervals to monitor the patient’s haematocrit; platelet count; activated partial 
thromboplastin time (aPTT), if concomitant heparinization is used; and possibly 
fibrinogen values. Monitoring of fibrinogen levels is controversial, although 
levels < 4.4 µmol/L (150 mg/dL) might indicate a clinically significant systemic 
effect. 
Comparison of plasminogen activators and dosages 
Plasminogen activators include streptokinase, uPA, tissue-type plasminogen 
activator (tPA; alteplase), tenecteplase (TNK), and recombinant tPA (r-
tPA; reteplase).  
The FDA has approved only streptokinase for systemic thrombolytic therapy of 
DVT. However, this agent is not currently recommended because of high rates 
of allergic reaction and bleeding complications and because of the availability 
of lower-risk agents. In the 1980s and 1990s, uPA was used extensively, but 
when it was temporarily taken off the market, tPA and r-tPA subsequently 
became the agents of choice. 
In a retrospective analysis of catheter-directed thrombolysis for DVT, no 
significant differences were observed between uPA, tPA, and r-tPA with regard 
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to success rate (>97%) or major complications (3-8%), although tPA and r-tPA 
were significantly less expensive than uPA. [16] 
Recommended continuous dosages for catheter-directed thrombolysis of 
unilateral leg DVT are as follows: 
 tPA - 0.5-1.0 mg/h 
 r-tPA - 0.25-0.75 U/h 
 TNK - 0.25-0.5 mg/h 
Other dosing options include an initial lacing dose, which entails an initial bolus 
given throughout the target thrombus, and a front-loaded dose, which is a high 
concentration given for the first few hours. No advantage to either approach has 
been demonstrated. 
Concomitant heparinization 
Most practitioners use concomitant heparinization. Full heparinization was 
commonly used in conjunction with uPA, whereas the current trend is to 
administer subtherapeutic heparin with tPA. Low-molecular-weight heparin 
(LMWH) has not been studied in this setting 
 
COMPLICATIONS:- 
The haemorrhagic complications of thrombolytic therapy are formidable 
(approximately 3 times higher than that of anticoagulant therapy) and include 
the small, but potentially fatal, risk of intracerebral haemorrhage. The 
62 
 
uncertainty regarding thrombolytic therapy is likely to continue. Currently, the 
American College of Chest Physicians (ACCP) consensus guidelines 
recommend catheter-directed thrombolytic therapy only for selected patients 
with extensive acute proximal DVT (eg, those with iliofemoral DVT, symptoms 
for less than 14 days, good functional status, and life expectancy of >1 year) 
who are at low risk of bleeding 
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INFERIOR VENACAVA FILTERS 
Inferior vena cava filters are not recommended in patients with acute venous 
thromboembolism (VTE) on anticoagulant therapy. 
These filters were developed in an attempt to trap emboli and minimize venous 
stasis. In most patients with deep venous thrombosis (DVT), prophylaxis 
against the potentially fatal passage of thrombus from the lower extremity or 
pelvic vein to the pulmonary circulation is adequately accomplished with 
anticoagulation. An inferior vena cava filter is a mechanical barrier to the flow 
of emboli larger than 4 mm.28,29 
The ideal vena cava filter would trap venous emboli while maintaining normal 
venous flow. Many different filter configurations have been used, but the 
current benchmark remains the Greenfield filter with the longest long-term data. 
Patency rates greater than 95% and recurrent embolism rates of less than 5% 
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have been demonstrated by numerous studies. The conical shape allows central 
filling of emboli while allowing blood on the periphery to flow freely. 
Numerous other filters with similar track records have since been developed, 
including filters that can be removed. 
Regardless of the type of filter placed, the technique remains the same. Local 
anaesthetic is used to anesthetize either the groin for a femoral vein approach or 
the neck for a jugular vein approach.  
A single wall needle is used under ultrasonic guidance to enter the target vein, 
and a 0.035-inch guide wire is passed into the inferior vena cava.  
A venogram is performed to identify the renal veins and measure the diameter 
of the vena cava to ensure the cava is not too big for the filter. Intravascular 
ultrasound (IVUS) can also be used for this purpose. It has the added benefit of 
not only allowing for bedside filter placement in sick intensive care unit (ICU) 
patients, but it also obviates the need for IV contrast. The correct filter location 
traditionally entails an infra-renal fixation with central filter extension to the 
level of the renal veins. Placement in the suprarenal inferior vena cava or 
superior vena cava may be indicated in some situations. 
American Heart Association recommendations for inferior vena cava filters 
include the following:- 
*Confirmed acute proximal DVT or acute PE in patient with contraindication 
for anticoagulation (this remains the most common indication for inferior vena 
cava filter placement) 
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*Recurrent thromboembolism while on anticoagulation 
*Active bleeding complications requiring termination of anticoagulation 
therapy 
Relative contraindications include the following: 
*Large, free-floating iliofemoral thrombus in high-risk patients. 
*Propagating iliofemoral thrombus while on anticoagulation 
*Chronic PE in patient with pulmonary hypertension and corpulmonale 
*Patient with significant fall risk 
Complications:- 
Migration 
Thrombosis 
Filter fracture 
IVC perforation 
Pulmonary embolism 
Device infection 
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 SURGICAL THROMBECTOMY:- 
Surgical thrombus removal has traditionally been used in patients with massive 
swelling and phlegmasia cerulea dolens. In many patients, fibrinolysis alone is 
highly effective, and it has become the primary treatment of choice for many 
forms of venous and arterial thrombosis.  
Unfortunately, when thrombosis is extensive, fibrinolysis alone may be 
inadequate to dissolve the volume of thrombus present. Even when the bulk of 
the thrombus is not excessive, many patients with thrombosis are poor 
candidates for fibrinolysis because of recent surgery or trauma involving the 
central nervous 
system or other noncompressible areas. Precisely defining the location and 
extent of thrombosis before considering any surgical approach to the problem is 
important.  
Duplex ultrasonography may sometimes be sufficient for this purpose, but 
venography (including routine contralateral iliocavography) is a more reliable 
guide to the anatomy and the particular pathology that must be addressed. 
The patient must be heparinized before the procedure. Traditional venous 
thrombectomy is performed by surgically exposing the common femoral vein 
and sapheno femoral junction through a longitudinal skin incision. A Fogarty 
catheter is passed through the clot, and the balloon is inflated and withdrawn, 
along with the clot. However, care must be taken to avoid dislodging the clot or 
breaking it into small fragments because pulmonary embolus will result. 
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A proximal balloon or a temporary caval filter may be used to reduce the 
likelihood of embolization. Venography is mandatory to confirm the clearance 
of the thrombus. Back bleeding does not indicate clot clearance because a patent 
valve can block flow, or flow can be present with patent tributaries. 
Venous valves may sometimes prevent the passage of a catheter in a retrograde 
direction down the leg. When this happens, the leg may be wrapped tightly with 
an Esmarch bandage in an attempt to force clot extrusion. After the thrombus 
has been removed, construction of a small arteriovenous fistula may assist in 
maintaining patency by increasing the flow velocity through a thrombogenic 
iliofemoral venous segment and promoting collateral development. The fistula 
is usually performed between the saphenous vein and the femoral vein. 
 To reduce the likelihood of rethrombosis, heparin anticoagulation is usually 
initiated before surgery, continued during the procedure, and maintained for 6-
12 months afterward. Leg compression devices are useful to maintain venous 
flow. 
Outcomes from multiple studies have shown rethrombosis rates around 12% 
when a temporary arteriovenous fistula is used. Optimal results were found in 
thrombosis less than 7 days, clearance of thrombus from the external and 
internal iliac veins, intraoperative venography, early ambulation, and religious 
use of compression stockings.  
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In a prospective randomized study from Sweden comparing surgery with 
anticoagulation, at 5 years, 37% of operated patients were asymptomatic, 
compared with just 18% in the anticoagulation group. Vein patency was 77% in 
the surgical group compared with just 30% in the anticoagulation group. 
 
 
                                     PROPHYLAXIS 
 
The patient who has undergone major abdominal or orthopaedic surgery, has 
sustained major trauma , or has prolonged immobilisation ( > 3 days ) represents 
an elevated risk for the development of venous thromboembolism12,13. The  
methods of prophylaxis can be mechanical or pharmacological. The simplest 
method is for the patient to walk. Activation of the calf pump mechanism is an 
effective means of prophylaxis , as evidenced by the fact that few active people 
without underlying factors develop venous thrombosis. 
The most common method of surgical prophylaxis has traditionally revolved 
around compression devices, which periodically compress the calves and 
essentially replicate the calf bellows mechanism. This has clearly reduced the 
incidence of venous thromboembolism in the surgical patient. The most likely 
mechanism for the efficacy of this device is prevention of venous stasis. 
Another traditional method of thromboprophylaxis has been the use of low-dose 
unfractionated heparin. The dosage traditionally used was 5000 U of 
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unfractionated heparin every 12 hours. More recently , a number of studies have 
revealed the efficacy of fractionated low-molecular weight heparin for the 
prophylaxis and treatment of venous thromboembolism. 
Comparison of LMWH with mechanical prophylaxis has demonstrated the 
superiority of LMWH for reduction of the development of venous 
thromboembolic disease 13,14,15. LMWH is considered the optimal method of 
prophylaxis for moderate- and high-risk patients. Even the traditional reluctance 
to use heparin in high-risk groups , such as the multiply injured patient and 
head-injured patient , must be re-examined , given the efficacy and safety 
profile of LMWH in multiple prospective trials. 
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MATERIALS AND METHODS 
 
THIS STUDY WAS CONDUCTED IN THANJAVUR MEDICAL COLLEGE 
FROM PERIOD OF SEPTEMBER 2016-2017. 
 
The study includes 100 patients presenting with complaints of lower limb pain, 
swelling admitted in surgical wards during the above mentioned period. 
Detailed history was taken and thorough physical examination was done. All 
details were recorded in the proforma designed prior to the commencement of 
the study. 
The recorded details include patients particulars, duration of condition, 
predisposing factors, details about previous medical or surgical illness, vitals 
monitored, basic blood investigations done. All patients were subjected to 
Doppler USG and involved segments noted. 
 
INCLUSION CRITERA 
 
1. Both sex, with age between 20-80 years 
2. Patients presenting with primary DVT 
3. Patients presenting with secondary DVT 
75 
 
EXCLUSION CRITERIA 
 
1. Age less than 20 and more than 80 
2. Patients not willing to be part of this study.  
 
STUDY DESIGN 
 
 This is an observational study conducted in our institution, Thanjavur 
Medical College during the period September 2016-2017. 
 Patients were subjected for Doppler ultrasound and region of thrombus 
identified . 
 All patients were treated with IV anticoagulants and improved.  Later 
changed to oral anticoagulants.  
 Young patients presenting within 6 hrs were treated with Catheter 
directed thrombolysis  using UROKINASE and showed improvement.  
 Patients were discharged and advised to continue oral anticoagulants. 
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RESULT 
1.  AGE 
Age Particulars 
No.of respondents 
(n=100) 
Percentage 
(100%) 
Below 20 1 1.0 
21 to 30 44 44.0 
31 to 40 23 23.0 
41 to 50 17 17.0 
Above 51 15 15.0 
Mean:35.98/S.D.:12.192/min.:20/max.:65 
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II.    SEX RATIO :- 
 
 
 
 
 
 
   
 
 
32
68
SEX RATIO
MALE
FEMALE
Particulars 
No.of 
respondents 
(n=100) 
Percentage 
(100%) 
MALE 
32 32.0 
FEMALE 
68 68.0 
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111) PREDISPOSING FACTORS 
 
 
 
 
  
 
 
 
 
 
12
37
27
24
0
5
10
15
20
25
30
35
40
MALIGNANCY POSTPARTUM POST SURGERY POST TRAUMA
PREDISPOSING FACTORS
Particulars 
No.of respondents 
(n=100) 
Percentage 
(100%) 
MALIGNANCY 12 12.0 
POST PARTUM 37 37.0 
POST SURGERY 27 27.0 
POST TRAUMA 24 24.0 
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IV REGION 
 
 
 
 
 
 
 
 
 
 
0 10 20 30 40 50 60 70 80
LEFT ILLIAC
B/L ILLIAC
IVC
LEFT ILLIOFEMORAL
LEFT ILLEOFEMORAL POPLITEAL
LEFT POPLITEAL
RIGHT ILLIAC
RIGHT ILLEO FEMORAL
RIGHT ILLEOFEMORAL POPLITEAL
2
6
3
71
2
1
1
13
1
Particulars 
 
 
 
No.of respondents 
(n=100) 
Percentage 
(100%) 
LEFT ILIAC 2 2.0 
BILATERAL ILIAC 6 6.0 
IVC 3 3.0 
LEFT ILIOFEMORAL 71 71.0 
LEFT ILIOFEMORAL POPLITEAL 2 2.0 
LEFT POPLITEAL 1 1.0 
RIGHR ILIAC 1 1.0 
RIGHT ILIOFEMORAL 13 13.0 
RIGHT ILIOFEMORALPOPLITEAL 1 1.0 
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V MANAGEMENT 
 
 
 
 
 
 
 
 
 
 
 
 
 
74
10
84
16
0
16
0
10
20
30
40
50
60
70
80
90
IMPROVED NOT IMPROVED TOTAL
Particulars 
IMPROVED NOT 
IMPROVED 
No.of 
respondents 
(n=100) 
Percentage 
(100%) 
MEDICAL 74 10 84 84.0 
CDT 16 0 16 16.0 
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VI.COMPLICATIONS 
 
 
 
 
 
 
 
 
 
 
 
 
90
5
1
3 1
COMPLICATIONS
NO COMPLICATIONS
POST THROMBOTIC ULCER
PULMONARY EMBOLISM
RECURRENCE
VARICOSE VEIN
Particulars 
No.of respondents 
(n=100) 
Percentage 
(100%) 
NO COMPLICATIONS 90 90.0 
POST THROMBOTIC ULCER 5 5.0 
PULMONARY EMBOLISM 1 1.0 
RECURRENCE 3 3.0 
VARICOSE VEIN 1 1.0 
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DISCUSSION 
In my study, most common age group was found to be between 21-30 
years 44%, followed by 31-40 years 23% , 41-50 17% , above 50-15%. 
Most common in females 68% 
Most common in postpartum period 37%, followed by post-surgery  27% , 
post trauma immobilization 24%, malignancy 12% 
Most common site of thrombosis was found to be LEFT ILIOFEMORAL  
71% , followed by RIGHT ILIOFEMORAL  13% , BILATERAL ILIAC 
6% , IVC 3% ,LEFT ILIOFEMEROPOPLITEAL 2 % , LEFT ILIAC 2 
%,RIGHT ILIAC 1%, RIGHT ILIOFEMEROPOPLITEAL 1 % AND 
LEFT POPLITEAL 1%. 
74% CASES RESPONDED WELL TO MEDICAL MANAGEMENT  
CDT was done for 16 patients and all of them improved. 
90 % patients improved with medical management and CDT, 10 % not 
improved and went for complications. 
COMPLICATIONS found were POST THROMBOTIC ULCER 5 %,  
RECURRENCE 3 % , VARICOSE VEIN 1 % PULMONARY 
EMBOLISM  1 %. 
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CONCLUSION 
Venous thromboembolism (VTE) is a serious preventable cause of 
morbidity & mortality in the world. DVT & pulmonary embolism (PE) are 
distinct but related aspects of VTE. 
Cancer patients undergoing surgical procedures have at least two times the 
risk of post-operative D.V.T. and greater than three times risk of fatal P.E. 
than noncancerous patients undergoing similar procedure. In elderly, 
D.V.T. is associated with 21% one-year mortality rate and P.E. is 
associated with 39% one-year mortality rate. 
P.E. is the leading cause of maternal death associated with childbirths. A 
woman’s risk of developing DVT is six times greater when she is 
pregnant. 
Evaluation and proper management is essential to decrease the burden of 
V.T.E. 
DOPPLER USG can easily find out DVT and anticoagulant therapy can 
effectively cure and prevent complications due to DVT. CATHETER 
DIRECTED THROMBOLYSIS when done in early time of presentation 
was found to be effective and without complications in this study. 
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SUMMARY 
This study was conducted in our institution, Thanjavur Medical College 
during September 2016-2017 to study the Epidemiology, Natural history, 
Treatment and Outcome of DVT.  
100 patients in the age group of 20-80 years were included in this study. 
Detailed history and physical examination was done for all the patients. 
Basic blood investigations were done. Doppler USG was done for all the 
patients to confirm the diagnosis and to find out the region affected. All 
patients were treated with anticoagulants. 16 patients underwent Catheter 
directed thrombolysis with urokinase. 
Mean age group was between 21-40 years. Most common in females and 
during postpartum period. 
Most common site was found to be LEFT ILIOFEMORAL VEIN. 
74% patients improved with medical management alone. 
Patients treated with CDT showed improvement without any 
complications. 
10 % patients treated with medical management experienced 
complications like post thrombotic ulcer, varicose vein, recurrence and 
pulmonary embolism. 
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ABBREVIATIONS 
PE  - pulmonary embolism 
VTE  - venous thromboembolism 
DVT  - deep vein thrombosis 
PGI2  - prostaglandin I2 
TPA  - tissue plasminogen activator 
ELISA - enzyme linked immunosorbent assay 
MRV  - magnetic resonance venography 
CV  -contrast venography 
Aptt  -activated partial thromboplastin time 
LMWH -low molecular weight heparin 
UFH  - unfractionated heparin 
PT  -prothrombin time 
INR  -international normalised ratio 
VKA  - vitamin K antagonist 
NT  -proBNP-N-terminal pro-brain natriuretic peptide 
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PROFORMA 
 
 
Serial No   :  
Name    : 
Age    : 
Sex    :  M/F 
Date of Admission  :         
Op/Ip number  : 
Co- morbidities  :  Diabetes/ Hypertension/ Ischaemic    
        Heart Disease/ Others 
Vitals at Arrival  : 
Temperature  : 
Pulse rate   : 
Respiratory Rate  : 
Blood pressure  : 
Complaints      : 
Pain-          Site                : 
  Duration : 
  Character : 
  Aggravating/Relieving Factors: 
Swelling 
 Site   : 
 Duration  : 
           Tenderness            : 
Skin over the Swelling :Normal / Redness / Ulcer  / Dialated Veins 
Distal Pulse    :Palpable/Not Palpable 
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Predisposing Factors :Pregnacy / Puerperium / Malignancy / Immobilisation 
     /Unknown Cause 
Immobilisation   : Duration : 
    Cause  : Surgery / Trauma /Post Partum 
Chest Pain    Duration  : 
                           Character : 
Dyspnea   : 
Haemoptysis   : 
Blood Investigations : 
Doppler-        Region     : 
    Complete / Parial Occlusion: 
Treatment    : Medical / Surgical 
Outcome   : Improved / Not Improved 
Complications of Treatment: 
Complications of Dvt  : 
 
 
  
91 
 
 
 MASTER CHART 
SL.NO NAME 
AG
E 
SEX 
PREDISPOSING 
FACTOR 
REGION 
MANAGE
MENT 
OUTCOME 
COMPLIC
ATION 
1 SATHYA 25 FEMALE POSTPARTUM 
LEFT 
ILIOFEMORAL 
M IMPROVED NO 
2 RAJAMMAL 55 FEMALE MALIGNANCY 
LEFT 
ILIOFEMORAL 
M IMPROVED NO 
3 BOOPATHY 36 FEMALE POST SURGERY 
LEFT 
ILIOFEMORAL 
M IMPROVED NO 
4 
KUNDHAIVAIDE
VI 
31 FEMALE POSTPARTUM 
LEFT 
ILIOFEMORAL 
M IMPROVED NO 
5 RAJENDRAN 62 MALE 
POST TRAUMA 
IMMOBILISATIO
N 
LEFT 
ILIOFEMORAL 
M IMPROVED NO 
6 SIVAKUMAR 38 MALE 
POST TRAUMA 
IMMOBILISATIO
N 
LEFT 
ILIOFEMORAL 
M IMPROVED NO 
7 JEYALAKSHMI 47 FEMALE POST SURGERY LEFT ILIAC  M IMPROVED NO 
8 RAJASEKAR 52 MALE POST SURGERY 
LEFT 
ILIOFEMORAL 
M IMPROVED NO 
9 ELAYARAJA 30 MALE 
POST TRAUMA 
IMMOBILISATIO
N 
RIGHT 
ILIOFEMORAL 
M IMPROVED NO 
10 KALAIMANI 33 FEMALE POST SURGERY 
LEFT 
ILIOFEMORAL 
M IMPROVED NO 
11 CHITRA 30 FEMALE POST SURGERY 
RIGHT 
ILIOFEMORALP
OPLITEAL 
M IMPROVED NO 
12 SUMATHI 38 FEMALE POST SURGERY 
LEFT 
ILIOFEMORAL 
M 
NOT 
IMPROVED 
VARICOSE 
VEIN 
13 KAVITHA 34 FEMALE POST SURGERY 
LEFT 
ILIOFEMORAL 
CDT IMPROVED NO 
14 SHANTHI 43 FEMALE MALIGNANCY 
RIGHT 
ILIOFEMORAL 
M IMPROVED NO 
15 RUSSIYA 55 FEMALE MALIGNANCY 
LEFT 
ILIOFEMORAL 
CDT IMPROVED NO 
16 SOORYA 25 FEMALE POST PARTUM 
LEFT 
ILIOFEMORAL 
M IMPROVED NO 
17 
PUNNIYAMMA
L 
65 FEMALE POST SURGERY BILATERAL ILIAC M IMPROVED NO 
18 PARAMASIVAM 35 MALE 
POST TRAUMA 
IMMOBILISATIO
N 
LEFT 
ILIOFEMORAL 
M 
NOT 
IMPROVED 
POST 
THROMB
OTIC 
ULCER 
19 VIVEK 22 MALE UNKNOWN 
LEFT 
ILIOFEMORAL 
M IMPROVED NO 
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SL.NO NAME AGE SEX 
PREDISPOSING 
FACTOR 
REGION 
MANAGE
MENT 
OUTCOME 
COMPLIC
ATION 
20 THANGAPPA 45 MALE 
POST TRAUMA 
IMMOBILISATIO
N 
RIGHT 
ILIOFEMORAL 
M IMPROVED NO 
21 DHAMAYANTHI 22 FEMALE POST PARTUM 
LEFT 
ILIOFEMORAL 
CDT IMPROVED NO 
22 VIJAYA 22 FEMALE 
POST TRAUMA 
IMMOBILISATIO
N 
LEFT 
ILIOFEMORAL 
M IMPROVED NO 
23 DHANASEKAR 37 MALE POST SURGERY 
LEFT 
POPLITEAL 
M IMPROVED NO 
24 MEENA 31 FEMALE POST PARTUM 
LEFT 
ILIOFEMORAL 
M IMPROVED NO 
25 KAVERI 30 FEMALE POST PARTUM 
LEFT 
ILIOFEMORAL 
M IMPROVED NO 
26 SUBRAMANIAN 51 MALE POST SURGERY 
LEFT 
ILIOFEMORAL 
M 
NOT 
IMPROVED 
 
PULMON
ARY 
EMBOLIS
M 
27 VASUDEVAN 42 MALE 
POST TRAUMA 
IMMOBILISATIO
N 
RIGHT 
ILIOFEMORAL 
M IMPROVED NO 
28 SUMATHY 27 FEMALE POST PARTUM 
LEFT 
ILIOFEMORAL 
CDT IMPROVED NO 
29 JEYALAKSHMI 26 FEMALE POST PARTUM 
LEFT 
ILIOFEMORAL 
M IMPROVED NO 
30 JEYARAMAN 65 MALE MALIGNANCY RIGHR ILIAC M IMPROVED NO 
31 VEERAIYIAN 38 MALE UNKNOWN 
LEFT 
ILIOFEMORAL 
M IMPROVED NO 
32 SELVI 20 FEMALE POST PARTUM 
LEFT 
ILIOFEMORAL 
CDT IMPROVED NO 
33 SUGANTHI 26 FEMALE POST PARTUM 
LEFT 
ILIOFEMORAL 
M IMPROVED NO 
34 MUTHU 50 FEMALE MALIGNANCY 
BILATERAL 
ILIAC 
M IMPROVED NO 
35 KATHIRVEL 35 MALE POST SURGERY 
LEFT 
ILIOFEMORAL 
M 
NOT 
IMPROVED 
RECURRE
NCE 
36 BABY 36 FEMALE POST SURGERY 
LEFT 
ILIOFEMORAL 
M IMPROVED NO 
37 
SENTHAMIL 
SELVI 
32 FEMALE POST PARTUM 
LEFT 
ILIOFEMORAL 
M IMPROVED NO 
38 SHARMILA 30 FEMALE POST PARTUM 
LEFT 
ILIOFEMORAL 
M IMPROVED NO 
39 
POOVANUAM
MAL 
45 FEMALE POST SURGERY 
LEFT 
ILIOFEMORAL 
M IMPROVED NO 
40 SARAVANAN 32 MALE MALIGNANCY IVC  M IMPROVED NO 
41 DHANAM 23 FEMALE POST PARTUM 
LEFT 
ILIOFEMORAL 
CDT IMPROVED NO 
42 RAJINI 42 MALE POST SURGERY 
LEFT 
ILIOFEMORAL 
CDT IMPROVED NO 
43 VEMKATESAN 45 MALE POST SURGERY 
LEFT 
ILIOFEMORAL 
M IMPROVED NO 
44 ANJALAI 24 FEMALE POST PARTUM 
LEFT 
ILIOFEMORAL 
M IMPROVED NO 
45 DHURVA 26 FEMALE POST PARTUM 
RIGHT 
ILIOFEMORAL 
M IMPROVED NO 
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SL.NO NAME AGE SEX 
PREDISPOSING 
FACTOR 
REGION 
MANAGE
MENT 
OUTCOME 
COMPLIC
ATION 
46 KANNIAYAN 51 MALE 
POST TRAUMA 
IMMOBILISATIO
N 
LEFT ILIAC  M IMPROVED NO 
47 MANI 42 MALE 
POST TRAUMA 
IMMOBILISATIO
N 
LEFT 
ILIOFEMORAL 
M IMPROVED NO 
48 SHRUTHI 28 FEMALE POST PARTUM 
LEFT 
ILIOFEMORAL 
M IMPROVED NO 
49 MANI 28 MALE UNKNOWN 
LEFT 
ILIOFEMORAL 
M IMPROVED NO 
50 TAMILARASI 47 FEMALE POST SURGERY 
LEFT 
ILIOFEMORAL 
M 
NOT 
IMPROVED 
RECURRE
NCE 
51 SWATHY 23 FEMALE POST PARTUM 
LEFT 
ILIOFEMORAL 
M IMPROVED NO 
52 RAJESHWARI 28 FEMALE POST PARTUM 
RIGHT 
ILIOFEMORAL 
M IMPROVED NO 
53 SAKTHI 48 FEMALE POST SURGERY 
LEFT 
ILIOFEMORAL 
POPLITEAL 
M IMPROVED NO 
54 CHITHRA 30 FEMALE POST PARTUM 
LEFT 
ILIOFEMORAL 
CDT IMPROVED NO 
55 POORNIMA 28 FEMALE 
POST TRAUMA 
IMMOBILISATIO
N 
LEFT 
ILIOFEMORAL 
M IMPROVED NO 
56 SUNDHARAM 40 MALE 
POST TRAUMA 
IMMOBILISATIO
N 
LEFT 
ILIOFEMORAL 
M IMPROVED NO 
57 MARYSTELLA 25 FEMALE POST PARTUM 
RIGHT 
ILIOFEMORAL 
M IMPROVED NO 
58 AYISA BANU 25 FEMALE POST PARTUM 
LEFT 
ILIOFEMORAL 
M IMPROVED NO 
59 JEEVA 43 FEMALE POST SURGERY 
LEFT 
ILIOFEMORAL 
M 
NOT 
IMPROVED 
POST 
THROMB
OTIC 
ULCER 
60 
MARIYA 
FRANCIS 
55 FEMALE MALIGNANCY IVC  M IMPROVED NO 
61 
DHANALAKSH
MI 
29 FEMALE POST PARTUM 
LEFT 
ILIOFEMORAL 
M IMPROVED NO 
62 THANIYAARASI 27 FEMALE POST PARTUM 
LEFT 
ILIOFEMORAL 
M IMPROVED NO 
63 THIYAGARAJAN 50 MALE MALIGNANCY 
BILATERAL 
ILIAC 
M IMPROVED NO 
64 SEETHA 31 FEMALE 
POST TRAUMA 
IMMOBILISATIO
N 
RIGHT 
ILIOFEMORAL  
M IMPROVED NO 
65 RAVI 49 MALE 
POST TRAUMA 
IMMOBILISATIO
N 
LEFT 
ILIOFEMORAL 
CDT IMPROVED NO 
66 SAVEETHA 24 FEMALE POST PARTUM 
LEFT 
ILIOFEMORAL 
CDT IMPROVED NO 
67 NATARAJAN 45 MALE POST SURGERY 
LEFT 
ILIOFEMORAL 
M IMPROVED NO 
68 MANOHARAN 40 MALE POST SURGERY 
LEFT 
ILIOFEMORAL 
M IMPROVED NO 
69 KUMAR 25 MALE UNKNOWN 
LEFT 
ILIOFEMORAL 
CDT IMPROVED NO 
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70 JAMMIAMMAL 55 FEMALE MALIGNANCY 
RIGHT 
ILIOFEMORAL 
M IMPROVED NO 
71 SELVI 28 FEMALE POST PARTUM 
LEFT 
ILIOFEMORAL 
M IMPROVED NO 
72 DHARANI 24 FEMALE POST PARTUM 
LEFT 
ILIOFEMORAL 
M IMPROVED NO 
73 GOMATHY 22 FEMALE POST PARTUM 
LEFT 
ILIOFEMORAL  
M IMPROVED NO 
74 NEELAMMAL 30 FEMALE POST SURGERY 
LEFT 
ILIOFEMORAL 
CDT IMPROVED NO 
75 MENNATCHI 32 FEMALE POST SURGERY 
LEFT 
ILIOFEMORAL 
M IMPROVED NO 
76 RAJA LAKSHMI 48 FEMALE MALIGNANCY 
BILATERAL 
ILIAC 
M IMPROVED NO 
77 THAMARAI 34 FEMALE 
POST TRAUMA 
IMMOBILISATIO
N 
RIGHT 
ILIOFEMORAL 
M IMPROVED NO 
78 YOGA LAKSHMI 23 FEMALE POST PARTUM 
RIGHT 
ILIOFEMORAL 
M IMPROVED NO 
79 KANIMOZHI 23 FEMALE POST PARTUM 
LEFT 
ILIOFEMORAL 
M IMPROVED NO 
80 ASWINI 27 FEMALE POST SURGERY 
LEFT 
ILIOFEMORAL 
CDT IMPROVED NO 
81 REVATHY 24 FEMALE POST PARTUM 
LEFT 
ILIOFEMORAL 
M IMPROVED NO 
82 ANJAMMAL 65 FEMALE POST SURGERY 
LEFT 
ILIOFEMORAL 
M 
NOT 
IMPROVED 
POST 
THROMB
OTIC 
ULCER 
83 SEBASTEIN 55 MALE 
POST TRAUMA 
IMMOBILISATIO
N 
BILATERAL 
ILIAC 
M 
NOT 
IMPROVED 
RECURRE
NCE 
84 
MUTHULAKSH
MI 
32 FEMALE POST PARTUM 
LEFT 
ILIOFEMORAL 
M IMPROVED NO 
85 MARIMUTHU 65 MALE MALIGNANCY IVC  M IMPROVED NO 
86 
VARATHA 
RAJAN 
55 MALE 
POST TRAUMA 
IMMOBILISATIO
N 
LEFT 
ILIOFEMORAL 
M IMPROVED NO 
87 
RAMACHANDR
AN 
42 MALE POST SURGERY 
LEFT 
ILIOFEMORAL 
POPLITEAL 
M IMPROVED NO 
88 MUNI 23 FEMALE POST PARTUM 
LEFT 
ILIOFEMORAL 
M IMPROVED NO 
89 BEGUM 35 FEMALE POST SURGERY 
LEFT 
ILIOFEMORAL 
M IMPROVED NO 
90 RANI 33 FEMALE POST PARTUM 
LEFT 
ILIOFEMORAL 
M IMPROVED NO 
91 DHIVYA 25 FEMALE POST PARTUM 
LEFT 
ILIOFEMORAL 
M IMPROVED NO 
92 
KALAYANA 
SUNDARAM 
30 MALE 
POST TRAUMA 
IMMOBILISATIO
N 
RIGHT 
ILIOFEMORAL 
M IMPROVED NO 
93 VANITHA 32 FEMALE POST SURGERY 
LEFT 
ILIOFEMORAL 
M 
NOT 
IMPROVED 
POST 
THROMB
OTIC 
ULCER 
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94 ANUSUYA 23 FEMALE POST PARTUM 
LEFT 
ILIOFEMORAL 
CDT IMPROVED NO 
95 PRAKASH 24 MALE 
POST TRAUMA 
IMMOBILISATIO
N 
LEFT 
ILIOFEMORAL 
M IMPROVED NO 
96 AYISABANU 24 FEMALE POST PARTUM 
LEFT 
ILIOFEMORAL 
M IMPROVED NO 
97 SANGEETHA 23 FEMALE POST PARTUM 
LEFT 
ILIOFEMORAL 
M IMPROVED NO 
98 BHARATHI 28 FEMALE POST PARTUM 
RIGHT 
ILIOFEMORAL 
CDT IMPROVED NO 
99 MOORTHY 65 MALE MALIGNANCY 
BILATERAL 
ILIAC 
M 
NOT 
IMPROVED 
POST 
THROMB
OTIC 
ULCER 
100 ABIRAMI 30 FEMALE POST PARTUM 
LEFT 
ILIOFEMORAL 
CDT IMPROVED NO 
 
